The Closing the HPV Testing Gap Act directs the National Institutes of Health to study the development of a standardized, noninvasive test for human papillomavirus (HPV) in men. Currently, no FDA-approved HPV diagnostic test exists for men, despite men experiencing significant HPV-related cancers, particularly oropharyngeal cancers. The study must examine various testing approaches including oral, pharyngeal, anal, penile, and urine testing, and assess feasibility of implementation across diverse and underserved populations. The NIH Director must complete the comprehensive study and submit findings to Congress within 30 months of enactment, including recommendations for developing the test and strategies for integrating it into national cancer prevention efforts. The legislation uses existing NIH appropriated funds for fiscal years 2026 through 2030 to support the research.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.